Involving Co-transfection Patents (Class 435/465)
  • Patent number: 9718871
    Abstract: Methods of generating sequence diversity in a protein, such as a ligand-binding protein, are provided. The methods comprise targeted introduction of two or more recombination signal sequences (RSSs) into the protein coding sequence and introduction of the modified protein coding sequence into a recombination-competent host cell, specifically a recombination-competent host cell that is capable of expressing at least RAG-1 and RAG-2, thereby allowing for recombination of the protein coding sequence and expression of variant proteins. Also provided are polynucleotides comprising a nucleic acid sequence encoding a target protein, such as a ligand-binding protein, and comprising two or more RSSs, and compositions and host cells comprising same.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 1, 2017
    Assignee: INNOVATIVE TARGETING SOLUTIONS INC.
    Inventors: Michael Gallo, Jaspal Singh Kang, Craig Robin Pigott, Abby Lin
  • Patent number: 9102943
    Abstract: The present invention provides a method for producing a virus vector, which comprises a step wherein cells that are capable of producing a virus vector are cultured in a culture medium that contains, as active components, a retinoic acid and a histone deacetylase inhibiting substance; and a culture medium for the production of a virus vector, which is characterized by containing, as active components, a retinoic acid and a histone deacetylase inhibiting substance.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: August 11, 2015
    Assignee: TAKARA BIO INC.
    Inventors: Kazuhisa Shinmura, Yoshinori Katayama, Kensuke Sakai, Toshihiro Shodai, Hirofumi Yoshioka, Junichi Mineno
  • Patent number: 9090673
    Abstract: Highly effective vaccine compositions are constructed according to the methods of this invention. The methods are amenable to use with any peptidic antigen sequence and involve covalent attachment of an immunostimulatory nucleotide sequence to an antigenic peptide sequence. Preferred antigenic peptides are fusion peptides made up of one or more CTL epitope peptides in sequence fused to a T helper peptide.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: July 28, 2015
    Assignee: CITY OF HOPE
    Inventor: Don J. Diamond
  • Patent number: 9057056
    Abstract: The N-acetylglucosaminyltransferase III activity is enhanced in a cell carrying retrovirus-origin gag-pol gene and env gene. By constructing a retrovirus vector with the use of the above cell, a retrovirus vector having a modified sugar chain structure can be obtained. The retrovirus vector constructed by this method shows a high infection efficiency particularly in the presence of a functional substance.
    Type: Grant
    Filed: September 28, 2005
    Date of Patent: June 16, 2015
    Assignee: TAKARA BIO INC.
    Inventors: Hideto Chono, Hiromi Okuyama, Tomoe Egashira, Nobuto Koyama, Junichi Mineno, Ikunoshin Kato
  • Publication number: 20150150152
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
  • Publication number: 20150118755
    Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 30, 2015
    Inventors: Rudolf Jaenisch, Yaqub Hanna, Marius Wernig, Christopher J. Lengner, Alexander Meissner, Oliver Tobias Brambrink, G. Grant Welstead, Ruth Foreman
  • Publication number: 20150079682
    Abstract: The invention includes compositions and methods for the selective expression of a target gene in a subset of cells. In certain embodiments, the present invention includes a construct comprising a first nucleic acid sequence comprising an episomal maintenance element and a second nucleic acid sequence comprising a target gene wherein the expression of the episomal maintenance element is regulated by a constitutive promoter and the expression of the target gene is regulated by a non-constitutive promoter. The construct is able to maintain episomal state, no matter whether the target gene is expressed in the cell.
    Type: Application
    Filed: February 27, 2013
    Publication date: March 19, 2015
    Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES
    Inventors: Baisong Lu, Qingguo Zhao, James Yoo, Anthony Atala
  • Publication number: 20150072431
    Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 12, 2015
    Inventors: Don HEALEY, Irina Tcherepanova, Melissa Adams, Atsushi Hinohara
  • Patent number: 8936908
    Abstract: The present invention relates to a method for the production of a permanent human cell line, wherein isolated primary human cells are transfected simultaneously with a sequence allowing the expression of at least one cell transforming factor and a sequence allowing the expression of at least one recombinant polypeptide.
    Type: Grant
    Filed: March 7, 2006
    Date of Patent: January 20, 2015
    Assignee: CEVEC Pharmaceuticals GmbH
    Inventors: Gudrun Schiedner, Christoph Volpers
  • Publication number: 20150011733
    Abstract: Disclosed are methods of making collagen 7, or functional fragments thereof, as well as collagen 7, and functional fragments thereof produced by such methods, nucleic acids encoding collagen 7, and functional fragments thereof, as well as vectors and host cells comprising such nucleic acids.
    Type: Application
    Filed: August 3, 2012
    Publication date: January 8, 2015
    Inventors: Malini Viswanathan, Mark DeSouza
  • Publication number: 20140356960
    Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector; a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.
    Type: Application
    Filed: April 25, 2014
    Publication date: December 4, 2014
    Inventor: Imre Berger
  • Publication number: 20140295489
    Abstract: The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake.
    Type: Application
    Filed: May 12, 2014
    Publication date: October 2, 2014
    Inventors: Yehuda G. Assaraf, Thomas Jostock, Hans-Peter Knopf
  • Publication number: 20140287511
    Abstract: Disclosed herein is the finding that Zscan4 is an early embryonic factor that facilitates cellular reprogramming. In particular, Zscan4 can replace the oncogenic reprogramming factor c-Myc to produce induced pluripotent stem cells when co-expressed with Klf4, Oct4 and Sox2. In addition, several Zscan4-dependent genes were identified that promote iPSC formation when co-expressed with known reprogramming factors. Thus, the present disclosure provides an ex vivo method of producing an iPS cell by reprogramming of a somatic cell. The method includes contacting the somatic cell with a Zscan4, or a Zscan4-dependent gene, and at least one reprogramming factor. Also provided are iPS cells produced by the disclosed method and non-human animals generated from such iPS cells.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 25, 2014
    Inventor: Minoru S.H. KO
  • Publication number: 20140273097
    Abstract: Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
    Type: Application
    Filed: May 28, 2014
    Publication date: September 18, 2014
    Applicant: Sangamo BioSciences, Inc.
    Inventors: Trevor Collingwood, Gregory J. Cost
  • Patent number: 8822223
    Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: September 2, 2014
    Assignee: Argos Therapeutics, Inc.
    Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
  • Publication number: 20140212922
    Abstract: Reverse engineering has offered new ways of studying the pathology of RNA viral infections, new more efficient devices of synthesizing recombinant viruses and developing vaccines and also demonstrated the versatility and efficiency of RNA dependent RNA polymerase RDRP system as an expression system. However, the currently used methods require a repertoire of complex, difficult-to-use tools. Present invention describes, a simpler plasmid based mammalian expression system that uses the RDRP enzyme activity for expression of recombinant proteins or RNA from viral minigenomes and rescue of recombinant viruses from cDNAs encoding entire genome(s) of negative stranded RNA viruses. This system will be useful for expression of recombinant proteins, therapeutic RNA molecules including anti-sense and/or selecting interfering RNA and Ribozymes. This system can also be used for gene therapy and producing recombinant viruses for production of new vaccines.
    Type: Application
    Filed: June 8, 2012
    Publication date: July 31, 2014
    Inventor: Vishwas Joshi
  • Patent number: 8771983
    Abstract: A method is disclosed for releasing the transcriptional regulation caused by a repeated sequence in a gene, a kit therefor and so on to thereby establish a system capable of producing a protein in a large amount.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: July 8, 2014
    Assignee: National University of Corporation Hiroshima University
    Inventor: Noriaki Shimizu
  • Patent number: 8741340
    Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: June 3, 2014
    Assignee: NsGene A/S
    Inventors: Philip Kusk, Lars Ulrik Wahlberg
  • Patent number: 8734851
    Abstract: The present invention provides implantable medical devices coated with polyelectrolyte assemblies that are fabricated by layer-by-layer deposition of nucleic acid and polycation. Such devices facilitate the local delivery of a nucleic acid contained in the polyelectrolyte assembly into a cell or tissue at an implantation site. Also provided are methods of fabricating and using implantable medical devices according to the invention.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: May 27, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David M. Lynn, Jingtao Zhang, Christopher M. Jewell, Nathaniel J. Fredin
  • Publication number: 20140140999
    Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.
    Type: Application
    Filed: November 15, 2013
    Publication date: May 22, 2014
    Applicant: MERUS B.V.
    Inventors: Cornelis A. DE KRUIF, Linda Johanna Aleida HENDRIKS, Ton LOGTENBERG
  • Patent number: 8716259
    Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: May 6, 2014
    Assignee: Replicor Inc.
    Inventors: Andrew Vaillant, Michel Bazinet
  • Publication number: 20140093485
    Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.
    Type: Application
    Filed: September 26, 2013
    Publication date: April 3, 2014
    Applicant: University Health Network
    Inventors: JEFFREY A. MEDIN, SEAN DEVINE
  • Publication number: 20140065178
    Abstract: The present invention provides pseudoinfectious alphavirus particles and methods of making them and using them to produce an immune response to an alphavirus in a subject.
    Type: Application
    Filed: February 1, 2012
    Publication date: March 6, 2014
    Applicant: UAB RESEARCH FOUNDATION
    Inventors: Ilya Frolov, Elena Frolova
  • Patent number: 8637315
    Abstract: Processes vectors and engineered cell lines for large-scale transfection and protein production in mammalian cells, especially Chinese Hamster Ovary (CHO) cells are described in which transfection efficiencies are realized through the use of a single vector system, the use of functional oriP sequences in all plasmids, the use of codon-optimized Epstein-Barr virus nuclear antigen-1 (EBNA1) constructs the use of a fusion protein between a truncated Epstein-Barr virus nuclear antigenen-1c (EBNA1c) protein and a herpes simplex virus protein VP16, the use of a 40 kDa fully deacetylated poly(ethylenimine) as a transfection reagent, the use of co-expression of a fibroblast growth factor (FGF) and/or the use of protein kinase B to potentiate heterologous gene expression enhancement by valproic acid (VPA).
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: January 28, 2014
    Assignee: National Research Council of Canada
    Inventors: Yves Durocher, Martin Loignon
  • Patent number: 8617533
    Abstract: Viral replicon selected nucleic acid expression libraries are useful for analyzing multiple antigens associated with a parasite, pathogen or neoplasia or for preparing immunogenic compositions for generating immune responses specific for the parasite, pathogen or neoplasia. Alphavirus replicon particles representative of the nucleic acid expression library are preferred. The nucleic acid library can be a random library, or it can be prepared after a selection step, for example, by differential hybridization prior to cloning into the replicon vector.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: December 31, 2013
    Assignee: AlphaVax, Inc.
    Inventors: Jonathan F. Smith, Kurt Kamrud, Sergey Dryga, Ian Caley
  • Publication number: 20130315872
    Abstract: The present invention provides a lentiviral vector system having a higher titer, while sustaining an excellent retrograde transport ability, particularly, in the brain. The present invention also provides a kit for preparing a retrograde transport viral vector comprising: (1) a packaging plasmid containing the gag gene and the pol gene of HIV-1; (2) a packaging plasmid containing an accessory gene of HIV-1; (3) a transfer plasmid containing an target gene (a transgene); and (4) an envelope plasmid containing, as an envelope gene, a gene encoding a fused polypeptide comprising a fused extracellular domain consisting of the N-terminal region of an extracellular domain of rabies virus glycoprotein (RV-G) and the C-terminal region of an extracellular domain of vesicular stomatitis virus glycoprotein (VSV-G), a transmembrane domain of RV-G or VSV-G, and an intracellular domain of VSV-G, and the like.
    Type: Application
    Filed: November 25, 2011
    Publication date: November 28, 2013
    Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventor: Kazuto Kobayashi
  • Patent number: 8592211
    Abstract: PiggyBac transposons and transposases with enhanced transposition activity in cells are provided. Also provided are associated methods and kits for both introducing exogenous DNA inserts into the genomes of host cells as well as for the removal of the inserts from the host cell genomes. Cells obtained by use of the compositions, methods and kits are also provided.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: November 26, 2013
    Assignee: The Rockefeller University
    Inventors: Ali Brivanlou, Arnaud Lacoste
  • Patent number: 8546645
    Abstract: The present invention relates to transgenic plants comprising a plurality of nucleic acids heterologous to said plant, each of said nucleic acid comprising a coding sequence operably linked to one or more regulatory elements for directing expression of said coding sequence in said plant, said nucleic acid being stably integrated at or adjacent to rDNA sequences, or a seed, organ, tissue, part or cell thereof, or a descendant of said plant, seed, organ, tissue, part or cell; methods of producing the transgenic plants; and methods of producing oil using the transgenic plants.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: October 1, 2013
    Assignee: Agrisoma Biosciences Inc.
    Inventors: Steven Fabijanski, Michael Lindenbaum, Ping Fu, Elizabeth-France Marillia
  • Patent number: 8524368
    Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: September 3, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David M. Lynn, Adam D. Miller
  • Patent number: 8513211
    Abstract: The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: August 20, 2013
    Assignee: Replicor Inc.
    Inventors: Andrew Vaillant, Michel Bazinet
  • Patent number: 8507269
    Abstract: Described herein are compositions and uses thereof related to Ca2+ release-activated Ca2+ (CRAC) channel activity. Also described herein CRAC channel modulators for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: August 13, 2013
    Assignee: CalciMedica, Inc.
    Inventors: Kenneth A. Stauderman, Jack Roos, Gonul Velicelebi
  • Patent number: 8486701
    Abstract: A method for modulating cell differentiation capabilities using heterologous gene expression. Some embodiments of the invention relate to a method for inducing a cardiac progenitor cell by delivering a reprogramming factor to the cell, wherein the reprogramming factor comprises ETS2 or a combination of ETS2 and Mesp1.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: July 16, 2013
    Assignees: University of Houston, Texas Heart Institute, The Texas A&M University System
    Inventors: Robert J. Schwartz, Vladimir N. Potaman, Jose Francisco Islas
  • Publication number: 20130164851
    Abstract: Provided herein are methods and compositions for generating a cell line capable of producing a biological product, using a gene amplification based system. Methods and compositions are provided to inhibit endogenous selectable amplifiable marker genes using RNA interference and prevent the selection of false positives during generation of a custom cell line. Such methods improve efficiency of cell line development and do not require the use of specialized substrates or cells lacking the endogenous selectable amplifiable marker gene to negate the effect of endogenously expressed levels of the selectable amplifiable marker gene in cells.
    Type: Application
    Filed: March 25, 2011
    Publication date: June 27, 2013
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Anthony Rossomando, Gregory P. Thill, Stuart Pollard
  • Publication number: 20130156736
    Abstract: A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells that are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 that expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell lines can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies.
    Type: Application
    Filed: March 27, 2012
    Publication date: June 20, 2013
    Inventors: Ronald VOGELS, Menzo Jans Emco Havenga, Majid Mehtall
  • Publication number: 20130143264
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Application
    Filed: June 28, 2012
    Publication date: June 6, 2013
    Applicant: SELEXIS SA
    Inventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
  • Patent number: 8444965
    Abstract: The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: May 21, 2013
    Assignee: University of Maryland, Baltimore County
    Inventors: Suzanne Ostrand-Rosenberg, Jacobus J. Bosch, Bruce R. Ksander
  • Publication number: 20130065311
    Abstract: A method of producing an induced pluripotent stem cell includes introducing into a somatic cell one or more non-viral expression vectors. The vectors include one or more of an Oct family gene, a Klf family gene, a Sox family gene, a Myc family gene, a Lin family gene, and Nanog gene. The somatic cell is then cultured in a medium that supports pluripotent stem cells. At least a portion of the one or more introduced non-viral expression vectors is not substantially integrated in the chromosome.
    Type: Application
    Filed: August 10, 2012
    Publication date: March 14, 2013
    Applicant: Kyoto University
    Inventors: Shinya Yamanaka, Keisuke Okita
  • Publication number: 20130052643
    Abstract: A method for generating a nuclear reprogrammed cell in accordance with the present invention includes the step of: introducing, into a somatic cell, (i) at least one gene selected from the group consisting of a gene encoding histone H2aa or a homologue thereof, a gene encoding histone H2ba or a homologue thereof, and a gene encoding a phosphorylation-mimic form of histone chaperon Npm2 or a phosphorylation-mimic form of a homologue of Npm2, and (ii) a nuclear reprogramming factor.
    Type: Application
    Filed: August 29, 2012
    Publication date: February 28, 2013
    Applicant: Riken
    Inventors: Shunsuke Ishii, Toshie Shinagawa
  • Publication number: 20130040302
    Abstract: Methods for producing engineered induced pluripotent stem (iPS) cells are provided comprising introducing a first nucleic acid into somatic cells for integration into their genome and reprogramming the cells to produce engineered iPS cells having the nucleic acid integrated into their genome. For example, in certain aspects the cells are reprogrammed by introduction of a genetic element that expresses one or more reprogramming factor and culturing of the cells under conditions sufficient to produce reprogrammed cells.
    Type: Application
    Filed: July 11, 2012
    Publication date: February 14, 2013
    Inventors: Thomas J. Burke, Michael Miller, Michael McLachlan, Sarah Jane Dickerson, Anne Strouse
  • Publication number: 20130029423
    Abstract: Provided are a method of improving the efficiency of establishment of iPS cells, comprising the step of contacting one or more substances selected from the group consisting of members of the GLIS family (e.g., GLIS1) and nucleic acids that encode the same and one or more substances selected from the group consisting of members of the Klf family and nucleic acids that encode the same, with a somatic cell, an iPS cell comprising an exogenous nucleic acid that encodes a member of the GLIS family or a member of the Klf family, that can be obtained by the method, and a method of producing a somatic cell by inducing the differentiation of the iPS cell.
    Type: Application
    Filed: February 16, 2011
    Publication date: January 31, 2013
    Applicants: Kyoto University, Japan Biological Informatics Consortium, National Institute of Advanced Industrial Science and Technology
    Inventors: Shinya Yamanaka, Naoki Goshima, Momoko Maekawa, Yoshifumi Kawamura, Hiromi Mochizuki
  • Patent number: 8362324
    Abstract: Nucleic acid sequences and methods are provided for producing plants and seeds having altered tocopherol content and compositions. The methods find particular use in increasing the tocopherol levels in plants, and in providing desirable tocopherol compositions in a host plant cell.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: January 29, 2013
    Assignee: Monsanto Technology LLC
    Inventors: Sai S. Subramaniam, Steven C. Slater, Katherine Karberg, Ridong Chen, Henry E. Valentin, Yun-Hua Huang Wong
  • Patent number: 8338180
    Abstract: The present invention provides methods of identifying an agent that inhibits an activity of a lentiviral Vif protein. The present invention provides methods of identifying an agent that increases the level of active APOBEC3G in a cell. The present invention provides agents identified by a subject screening method; and further provides methods for treating lentivirus infections.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: December 25, 2012
    Assignee: The J. David Gladstone Institutes
    Inventors: Warner C. Greene, Kimberly S. Stopak, Carlos M. C. deNoronha, Wesley M. Yonemoto
  • Publication number: 20120316066
    Abstract: The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.
    Type: Application
    Filed: December 2, 2011
    Publication date: December 13, 2012
    Applicant: Intrexon Corporation
    Inventors: Robert Eugene HORMANN, Bing Li
  • Publication number: 20120301438
    Abstract: The present invention is based on the seminal discovery that cord blood (CB) and adult bone marrow (BM) CD34+ cells can be reprogrammed to early stem cells. The invention provides the reprogramming of CB and adult bone marrow (BM) CD34+ cells from subjects without any pre-treatment. Provided are methods for reprogramming blood cells of a subject. Also provided are methods of disease modeling and methods of generating subject-specific differentiated cells. In addition, the invention provides methods of identifying an agent that alters a function of subject-specific differentiated cells as well as isolated pluripotent or multipotent stem cells reprogrammed from blood cells.
    Type: Application
    Filed: September 14, 2010
    Publication date: November 29, 2012
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventor: Linzhao Cheng
  • Publication number: 20120295964
    Abstract: Provided is a lentiviral vector system which sustains a high-frequency retrograde transportation ability in animal brain and has a higher titer. A kit for preparing a retrograde transport viral vector, which comprises: (1) a packaging plasmid containing the gag gene and pol gene of HIV-1; (2) a packaging plasmid containing an accessory gene of HIV-1; (3) a transfer plasmid containing a target gene; and (4) an envelope plasmid containing, as an envelope gene, a gene encoding a fused polypeptide comprising the extracellular domain of rabies virus glycoprotein (RV-G), the transmembrane domain of rabies virus glycoprotein (RV-G) or vesicular stomatitis virus glycoprotein (VSV-G) and the intracellular domain of vesicular stomatitis virus glycoprotein (VSV-G).
    Type: Application
    Filed: November 11, 2010
    Publication date: November 22, 2012
    Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventor: Kazuto Kobayashi
  • Publication number: 20120276579
    Abstract: The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake.
    Type: Application
    Filed: June 13, 2012
    Publication date: November 1, 2012
    Applicant: NOVARTIS AG
    Inventors: Yehuda G. Assaraf, Thomas Jostock, Hans-Peter Knopf
  • Publication number: 20120270322
    Abstract: The present disclosure provides a DNA molecule capable of replication in Mycobacteria having a nucleic acid sequence as disclosed in SEQ ID NO: 1, a shuttle vector constructed using it and a transformed cells containing the present vector. The vector of about 18 kb of the present disclosure contains 16 ORFs, a replication origin and a rep-like protein essential for replication. Therefore, the plasmid of the present disclosure can be utilized as a gene delivery system/research, and also in a therapeutic system such as immune therapeutics by effectively delivering proteins or heterologous DNA and expressing the encoded DNA in cells.
    Type: Application
    Filed: April 19, 2012
    Publication date: October 25, 2012
    Applicant: SNU R&DB Foundation
    Inventors: Bum-Joon KIM, Hyungki LEE
  • Publication number: 20120263689
    Abstract: Methods and compositions for generating adipose-derived induced pluripotent stem cells for humans and animals and their use are provided.
    Type: Application
    Filed: September 10, 2010
    Publication date: October 18, 2012
    Applicant: The Salk Institute for Biological Studies
    Inventors: Shigeki Sugii, Ronald M. Evans, Juan Carlos Izpisua Belmonte, Yasuyuki Kida
  • Patent number: 8211631
    Abstract: A population of iPS cells derived from somatic cells from a spinal muscular atrophy patient is disclosed. In one embodiment of the invention, the cells have been cultured to produce neural cells. In another embodiment, the invention is a method of testing compounds for their ability to modify cellular SMN levels comprising the steps of obtaining a population of iPS cells derived from a spinal muscular atrophy patient or cells derived from the iPS cells, and examining the effect of a test compound on SMN levels.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: July 3, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Clive Svendsen, Allison Ebert
  • Publication number: 20120135015
    Abstract: Methods for generating pancreatic stem cells from a pancreatic tissue of 24-week old mice by transient overexpression of reprogramming factors combined with Pdx1 selection is described herein. The generated cells were designated as iPaS (induced pancreatic stem) cells and exhibit the same morphology as the pancreatic stem cells previously established from young donors without genetic manipulation and express genetic markers of endoderm and pancreatic progenitors. Transplantation of the iPaS cells into nude mice resulted in no teratoma formation. Moreover, iPaS cells were able to differentiate into insulin-producing cells more efficiently than ES cells. In addition, the technology of transient overexpression of reprogramming factors and tissue-specific selection of the present invention may also be useful for the generation of other tissue-specific stem cells.
    Type: Application
    Filed: September 19, 2011
    Publication date: May 31, 2012
    Applicant: Baylor Research Institute
    Inventors: Hirofumi Noguchi, Marlon F. Levy, Shinichi Matsumoto